| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000064874A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/15/2001 | WO2000059497A8 Pyrrolidine modulators of chemokine receptor activity |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000056866A3 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 02/15/2001 | WO2000054759A3 Lxr modulators |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000039154A8 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 02/15/2001 | WO2000011204A3 Homer interacting proteins |
| 02/15/2001 | WO1999042102A8 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 02/15/2001 | DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases |
| 02/15/2001 | DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin |
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | DE19936521A1 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate Substituted pyrrolidine-2,3,4-trione-3-oxime Derivatives |
| 02/15/2001 | CA2382759A1 Agent for the remedy of neural damage having a nitrogen-containing compound as the active ingredient |
| 02/15/2001 | CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | CA2381910A1 Novel vitamin d analogues |
| 02/15/2001 | CA2381699A1 Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators |
| 02/15/2001 | CA2381621A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | CA2381325A1 Polynucleotides regulating the activation of the expression of a gene in the heart and its uses in gene therapy |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2380981A1 Fluorene derivatives |
| 02/15/2001 | CA2380973A1 Substituted pyrrolidine-2-3,4-trione 3-oxime derivatives which are active as nmda receptor antagonists |
| 02/15/2001 | CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | CA2379977A1 Novel integrin receptor antagonists |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2379047A1 Nitroxy derivatives of (r) and (s)-carnitine |
| 02/15/2001 | CA2378401A1 Implantable active ingredient depot |
| 02/15/2001 | CA2348959A1 Methods of cytoprotection using an enantiomer of estrogen of ischemic damage |
| 02/15/2001 | CA2346291A1 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/14/2001 | EP1076091A1 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 02/14/2001 | EP1076066A1 Peptides for lowering blood glucose levels |
| 02/14/2001 | EP1075840A2 Therapeutic and prophylactic uses of antithrombin III |
| 02/14/2001 | EP1075529A1 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 02/14/2001 | EP1075528A1 Endothelin-converting-enzyme like protein |
| 02/14/2001 | EP1075496A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075476A1 Novel benzimidazoles and benzoxazoles |
| 02/14/2001 | EP1075475A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 02/14/2001 | EP1075474A1 Process for making 1,3-disubstituted-4-oxocyclic ureas |
| 02/14/2001 | EP1075473A1 Process for making 1,3-disubstituted-4-oxocyclic ureas |
| 02/14/2001 | EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| 02/14/2001 | EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 02/14/2001 | EP1075466A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 02/14/2001 | EP1075260A2 Novel fatty acid analogues for the treatment of primary and secondary restenosis |
| 02/14/2001 | EP1075259A1 Novel fatty analogues for the treatment of diabetes |
| 02/14/2001 | EP1075258A1 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
| 02/14/2001 | EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 02/14/2001 | EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS |
| 02/14/2001 | EP0815120B1 17-difluoromethylene-oestratrienes |
| 02/14/2001 | EP0773964B1 Gas phase production of polydienes |
| 02/14/2001 | EP0738280B1 Superactive vip antagonists |
| 02/14/2001 | CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system |
| 02/14/2001 | CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof |
| 02/14/2001 | CN1284066A Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 02/14/2001 | CN1284058A Neuroprotective agents |
| 02/14/2001 | CN1283628A Extract of shark cartilage and its preparing process |
| 02/14/2001 | CN1283623A 1,2,4,5-tetrahydro-benzo[d] azepine compound |
| 02/14/2001 | CN1283622A 6-hydroxy-3(4-[2-(piperidine-1-group)oxyethyl group]phenoxy)-2-(4-methoxy phenyl) benzo[b] thiophene hydrochloride salt |
| 02/14/2001 | CN1283499A Aseptic 'Shenmai' powder for injection and its preparing process |
| 02/14/2001 | CN1283497A Oral liquid for treating cerebrovascular disease and its preparing process |
| 02/14/2001 | CN1283485A Instant particles 'Xinnaotong' for treating heart and brain diseases |
| 02/14/2001 | CN1283484A Chinese-medicine for treating hypertension and its preparing process |
| 02/14/2001 | CN1283482A Medicinal composition for treating cardiovascular disease and its preparing process |
| 02/14/2001 | CN1283480A Medicine for treating piles |
| 02/14/2001 | CN1283473A Medicine for treating cardiovascular and cerebrovascular apoplexy and applexy aurae and its preparing process |
| 02/14/2001 | CN1283471A Tea for nursing cardiac and cerebral blood vessel |
| 02/14/2001 | CN1283463A Process for preparing solid-state-microspherical vascular suppository of sodium alginate |
| 02/14/2001 | CN1283462A Application of astragalin A in preparing medicinal composition |
| 02/14/2001 | CN1061889C Pile eliminating powder |
| 02/14/2001 | CN1061882C Chinese medicine for treating apoplexy |
| 02/13/2001 | US6187932 Subjecting n-(d-alpha-methyl-beta-acylthiopropionyl)-l-proline to hydrolysis reaction in aqueous medium in presence of strong acid at specified temperature to remove acyl group, isolating captopril |
| 02/13/2001 | US6187820 Administering compounds such as n,n-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine hydrochloride for prophylaxis or treatment of hyperlipidemia, hypercholesterolemia or hypertriglyceridemia |
| 02/13/2001 | US6187810 Administering to improve the therapeutic effect and the bioavailability of known medicaments; administering to diminish acute or chronic toxicity of a natural alkaloid, cardiac glycoside or synthetic drug |
| 02/13/2001 | US6187798 Heterocyclic compounds |
| 02/13/2001 | US6187778 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists |
| 02/13/2001 | US6187777 Pyrrolo(3,2-d)pyrimidine derivatives; neuropeptide y and corticotropin releasing factor modulators; dietetics; antidiabetic, antiinflammatory, and antitumor agents |
| 02/13/2001 | US6187772 Pyrroloazepine compounds |
| 02/13/2001 | US6187771 Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| 02/13/2001 | US6187769 Benzoxazepine derivatives and their salts and medicaments containing the same |
| 02/13/2001 | US6187767 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| 02/13/2001 | US6187587 Nucleotide sequences; for diagnosis and treatment of related disorders |
| 02/13/2001 | US6187562 Polynucleotides encoding human sphingosine Lyase |
| 02/13/2001 | US6187542 Diagnosing humans with congestive heart failure; obtaining leukocyte sample, detecting mutation in gene coding hydrolase, the presence of mutation indicates sensitivity to congestive heart failure |
| 02/13/2001 | US6187314 Provide a more accurately defined ginkgo biloba extract by further identifying individual components of the flavonoid compounds, determining the amount of the individual components and regulating the ratio among them. |
| 02/13/2001 | US6187304 Effects of IFN-γ on cardiac hypertrophy |
| 02/13/2001 | CA2315588A1 Use of antithrombin iii for the prophylaxis and therapy of diseases |
| 02/13/2001 | CA2192674C Methods for treating respiratory disease |
| 02/13/2001 | CA2170065C Amide-derived bi-aromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses |
| 02/13/2001 | CA2067653C Modified complement system regulator |
| 02/12/2001 | CA2280249A1 Vanadium compounds as anti-angiogenics and as inhibitors of endothelin production |
| 02/10/2001 | WO2001032871A2 Follistatin-related protein zfsta4 |
| 02/10/2001 | CA2389956A1 Follistatin-related protein zfsta4 |
| 02/08/2001 | WO2001055118A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient |
| 02/08/2001 | WO2001009612A1 Modulating binding site on potassium channels used for screening |
| 02/08/2001 | WO2001009390A1 Tenascin-c nucleic acid ligands |
| 02/08/2001 | WO2001009342A1 Microencapsulated nitric oxide synthase source |
| 02/08/2001 | WO2001009319A1 Gene expressed specifically in human fetal heart muscle |